Literature DB >> 9568661

Biliary surgery after heart transplantation.

F Menegaux1, R Dorent, D Tabbi, A Pavie, J P Chigot, I Gandjbakhch.   

Abstract

BACKGROUND: Biliary tract diseases are frequent in heart transplant recipients, with significant morbidity and mortality. Since the first presentation of gallstones in this population is often acute cholecystitis, asymptomatic cholelithiasis should not be considered benign. PATIENTS AND METHODS: We retrospectively reviewed 18 heart transplant recipients who underwent cholecystectomy from January 1991 to June 1997. We intentionally chose to perform a straightforward open procedure when acute cholecystitis was suspected (3 patients). A laparoscopic cholecystectomy was performed in all the other cases (15 patients) without conversion to open procedure.
CONCLUSION: Since no significant complications were observed in our patients, we believe that transplant recipients with cholelithiasis should undergo laparoscopic cholecystectomy in their posttransplantation course regardless of the symptomatic status of their biliary tract.

Entities:  

Mesh:

Year:  1998        PMID: 9568661     DOI: 10.1016/s0002-9610(98)00008-7

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  Prophylactic cholecystectomy in transplant patients: a decision analysis.

Authors:  Lillian S Kao; Christopher Flowers; David R Flum
Journal:  J Gastrointest Surg       Date:  2005 Sep-Oct       Impact factor: 3.452

2.  Gallstone disease in heart transplant recipients.

Authors:  William S Richardson; Walter J Surowiec; Kristine M Carter; Todd P Howell; Mandeep R Mehra; John C Bowen
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

Review 3.  Emergency abdominal surgery after solid organ transplantation: a systematic review.

Authors:  Nicola de'Angelis; Francesco Esposito; Riccardo Memeo; Vincenzo Lizzi; Aleix Martìnez-Pérez; Filippo Landi; Pietro Genova; Fausto Catena; Francesco Brunetti; Daniel Azoulay
Journal:  World J Emerg Surg       Date:  2016-08-30       Impact factor: 5.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.